Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Through the first nine months of 2024, Moderna's revenue of $2.3 billion represents a 44% decline year over year. This figure includes a mere $10 million in sales of the new RSV vaccine following ...

The mRNA-1018 vaccine has produced “positive preliminary data” in a phase 1/2 study, according to Moderna, which plans to unveil the findings at an upcoming medical conference. The HHS said ...

Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

Erica Denhoff / Icon Sportswire via Getty Images Moderna ... a vaccine that could be used to fight bird flu. The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study ...

In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.